BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides
Year: 2017
Type: article
Study design: Clinical Trial
DOI: 10.1002/jcph.950
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: closed
Funder: AstraZeneca
OpenAlex ID: W2626081108
